Bexobrutideg Shows Strong Phase 1 Results in WM Trial
BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...
Oncology
Advertisement
Columvi Combo Doubles Survival in Three-Year STARGLO Results
Basel, 8 December 2025 — Roche has reported three-year follow-up findings from the pivotal phase III STARGLO study, demonstrating...
UroGen Pharma Expands Oncology Capabilities With New Inducement Grants
PRINCETON, N.J., December 5, 2025 — UroGen Pharma Ltd. has announced the issuance of inducement restricted stock units (RSUs)...
BriaCell Reveals New Phase 2 and Phase 3 Data Ahead of SABCS 2025
Philadelphia, PA and Vancouver, BC — December 2, 2025 — BriaCell Therapeutics Corp. announced plans to present three major...
Junshi Biosciences Phase 3 Trial Confirms JS001sc Success in NSCLC
SHANGHAI, China, Nov. 25, 2025 — Junshi Biosciences announced that its Phase 3 clinical study evaluating JS001sc, a subcutaneous...
Advertisements
Telomir-1 Shows Strong Leukemia Cell-Killing Activity
WILMINGTON, DE — November 21, 2025 — Telomir Pharmaceuticals announced new preclinical findings showing that its investigational compound Telomir-1...
Zipalertinib Advances With FDA Rolling NDA Submission
PRINCETON, NJ — November 20 , 2025 — Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced the initiation of...
FDA Approves Accord BioPharma’s Denosumab Biosimilars, Expanding Access to Bone-Health Therapy
Durham, North Carolina, November 2025 Accord BioPharma has announced FDA approval of two denosumab biosimilars, OSVYRTI (denosumab-desu) and JUBEREQ...
AbbVie’s Epkinly Gets FDA Nod for Follicular Lymphoma Combo
NORTH CHICAGO, IL – November 18, 2025 — AbbVie announced that the U.S. Food and Drug Administration (FDA) has...
Five-Year REZLIDHIA Data Reinforces Long-Term AML Outcomes
Dateline IntroductionNovember 18, 2025 — South San Francisco, CA — Rigel Pharmaceuticals has published final five-year clinical data on...
Advertisement
